Kiniksa Pharmaceuticals International (KNSA) Income towards Parent Company (2021 - 2025)
Historic Income towards Parent Company for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $18.4 million.
- Kiniksa Pharmaceuticals International's Income towards Parent Company rose 24523.75% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 14299.03%. This contributed to the annual value of -$43.2 million for FY2024, which is 2848.49% up from last year.
- As of Q3 2025, Kiniksa Pharmaceuticals International's Income towards Parent Company stood at $18.4 million, which was up 24523.75% from $17.8 million recorded in Q2 2025.
- Over the past 5 years, Kiniksa Pharmaceuticals International's Income towards Parent Company peaked at $224.1 million during Q3 2022, and registered a low of -$49.5 million during Q1 2021.
- In the last 5 years, Kiniksa Pharmaceuticals International's Income towards Parent Company had a median value of -$12.7 million in 2024 and averaged $2.3 million.
- Per our database at Business Quant, Kiniksa Pharmaceuticals International's Income towards Parent Company soared by 83367.27% in 2022 and then tumbled by 15562.53% in 2023.
- Over the past 5 years, Kiniksa Pharmaceuticals International's Income towards Parent Company (Quarter) stood at -$44.1 million in 2021, then skyrocketed by 300.84% to $88.5 million in 2022, then tumbled by 155.63% to -$49.2 million in 2023, then soared by 81.95% to -$8.9 million in 2024, then soared by 307.41% to $18.4 million in 2025.
- Its Income towards Parent Company stands at $18.4 million for Q3 2025, versus $17.8 million for Q2 2025 and $8.5 million for Q1 2025.